Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Alexander Dimitri¹²³, Friederike Herbst²³⁴ and Joseph A. Fraietta¹²³⁵*

Abstract
Chimeric Antigen Receptor (CAR) T-cells represent a breakthrough in personalized cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition, signaling, and costimulatory domains are used to reprogram T-cells to target tumor cells for destruction. Despite the success of this approach in refractory B-cell malignancies, optimal potency of CAR T-cell therapy for many other cancers, particularly solid tumors, has not been achieved. Factors such as T-cell exhaustion, lack of CAR T-cell persistence, cytokine-related toxicities, and bottlenecks in the manufacturing of autologous products have hampered the safety, effectiveness, and availability of this approach. With the ease and accessibility of CRISPR-Cas9-based gene editing, it is possible to address many of these limitations. Accordingly, current research efforts focus on precision engineering of CAR T-cells with conventional CRISPR-Cas9 systems or novel editors that can install desired genetic changes with or without introduction of a double-stranded break (DSB) into the genome. These tools and strategies can be directly applied to targeting negative regulators of T-cell function, directing therapeutic transgenes to specific genomic loci, and generating reproducibly safe and potent allogeneic universal CAR T-cell products for on-demand cancer immunotherapy. This review evaluates several of the ongoing and future directions of combining next-generation CRISPR-Cas9 gene editing with synthetic biology to optimize CAR T-cell therapy for future clinical trials toward the establishment of a new cancer treatment paradigm.

Keywords: CRISPR, CAR T-cell, Gene editing, Immunotherapy, Cancer

Background
The utility of CRISPR-Cas9 technology has led to a surge in applying genome editing approaches to combat a variety of genetic disorders and cancers. In these cases, inherited genetic diseases with known gene mutations can be corrected [1, 2]. This technology can also be applied to induce specific mutations in the setting of in vitro and in vivo experimental models of disease to study various interventional strategies. In the context of T-cell-based immunotherapies, applications of CRISPR-Cas9 technology are being explored to improve T-cell effector function and persistence, reduce treatment-related toxicity, and increase patient product availability [3, 4].

Main text
Overview of chimeric antigen receptor T-cell therapy and resistance mechanisms
CAR T-cell therapy has led to sustained remissions in populations of otherwise refractory patients and, more specifically, has demonstrated complete response rates of >80–97% in certain B-cell malignancies such as acute lymphoblastic leukemia (ALL) [5, 6]. Because of this clinical efficacy, preclinical development of CAR T-cell therapy for several other cancer types is an area of active investigation, and the future of cellular immunotherapy will undoubtedly be extensive and dynamic. In the setting of conventional CAR T-cell therapy, a patient’s...
own T-cells are genetically engineered to express a synthetic receptor that recognizes a specific target antigen on tumor cells. The specificity and activation of the CAR T-cells typically result from combining extracellular antigen-binding domains from antibodies (e.g., single-chain variable fragments, scFvs; heavy-chain variable domain (VHH)-based binders) with the intracellular signaling machinery of the T-cell receptor (TCR) CD3ζ chain. Additional co-stimulation is provided in tandem with the signaling domains of molecules such as CD28 or 4-1BB to further potentiate T-cell activation and persistence (Fig. 1) [7–9]. The first United States Food and Drug Administration (FDA)-approved applications of CAR T-cell therapy occurred in 2017 with the release of the commercial CD19-directed CAR T-cell therapies Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) that are used to treat B-cell ALL and diffuse large B-cell lymphoma (DLBCL) [7, 10, 11]. While CD19 is a transmembrane glycoprotein continuously and stably expressed on all stages of B-cell lineage differentiation and is thus present on healthy as well as malignant B-cells, aplasia resulting from CD19 CAR T-cell administration is clinically tolerated and made feasible through immunoglobulin replacement therapy [12]. Since then, other CD19 CAR T-cell products, as well as the first non-CD19 directed CAR targeted to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma, have been approved [10, 13–15]. Additionally, numerous clinical trials are currently underway to assess the safety and efficacy of CAR products for hematopoietic malignancies and non-hematopoietic cancers. These next-generation products incorporate single antigen binders, tandem CARs and co-expressed receptors against multiple tumor targets, logic-gated receptors, and engineered delivery of payloads to enhance effector T-cell function [10, 16].

Despite these developments, the causes of unsuccessful CAR T-cell therapy are multifactorial and may not be addressed with synthetic biological improvements alone. Major limitations to successful CAR T-cell therapy occur both during the manufacturing process in vitro and during CAR T-cell proliferation in vivo. In many B-cell malignancies, complete responses are associated with robust CAR T-cell proliferation, with a clear advantage of long-term CAR T-cell persistence [6, 17–21]. Thus, limited CAR T-cell expansion and persistence following therapy is a common mechanism of treatment failure. Lack of therapeutic levels of in vivo CAR T-cell proliferation and persistence can be attributed in part to the pre-existing exhausted state of baseline or manufactured

Fig. 1 Schematic representation of a chimeric antigen receptor (CAR) T-cell. CART-cells are typically produced by transducing T-lymphocytes with a transgene encoding a synthetic antigen receptor. This transgene is integrated into the T-cell genome, transcribed and translated into a CAR protein. The core functional components of a CAR are binding and signaling domains separated into extracellular and intracellular compartments, respectively. The extracellular binding portion of the receptor is typically comprised of a single-chain variable fragment derived from the variable regions of an antibody that recognizes specific tumor antigens, together with a spacer that provides flexibility to the binding domain. The transmembrane domain connects the binding domain with intracellular signaling moieties. The TCR-derived CD3ζ chain drives T-cell activation and is fused in tandem with co-stimulatory endodomains that allow for robust and sustained function.
T-cells (e.g., in chronic lymphocytic leukemia [CLL]), acquisition of CAR T-cell hypofunction following infusion [20, 22–24], a reduction in stem cell memory/central memory differentiation [20, 25–28] and premature senescence [23]. There are also many patients who cannot benefit from this therapy because of issues with collecting their autologous T-cells, especially from subjects receiving intensive chemotherapy and with low numbers of memory T-cells that possess optimal proliferative capacity [20, 26].

Additional hurdles are specific to solid tumors where CAR T-cells must traffic to tumor sites and surmount stromal barriers to infiltrate the tumor bed and elicit tumor-specific cytotoxicity. Even if trafficking and infiltration are successful, T-cells can become dysfunctional due to a toxic tumor microenvironment (TME) characterized by metabolic perturbations, the presence of inhibitory soluble factors and cytokines, as well as elevated frequencies of suppressive immune cells or tumor cells that secrete these mediators and overexpress ligands for negative immune checkpoint receptors. Malignant cells also undergo antigen loss or downregulation to escape and evade CAR T-cell recognition at the tumor site. Potential CAR T-cell therapy patients may also experience advanced disease progression during the prolonged process of gaining enough quality T-cells for manufacturing. The above issues cannot be addressed with a single approach. However, many of these challenges may be overcome by using site-specific genetic editing in combination with next-generation cellular engineering approaches. With the genesis of easily multiplexable precision genome editing using clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) (CRISPR-Cas9) technology [29], there is an opportunity to circumvent many of these barriers to CAR T-cell therapy of cancer and fast-track integration of this treatment approach into routine medical management of a variety of malignancies.

**CRISPR-Cas9 gene editing modalities**

The emergence of CRISPR-Cas9 technology with its simplicity, flexibility, and effectiveness has considerably improved the process and time frame of gene editing. Briefly, the Cas9 DNA endonuclease enzyme can be directed to virtually any site in the genome to create a double-stranded DNA break. The cleavage region for Cas9 is selected based on a 20-base pair single guide RNA sequence (sgRNA) that directs Cas9 to the target DNA cut site, which possesses sequence complementarity to the sgRNA. This site is additionally specified by a protospacer adjacent motif (PAM) sequence within the target DNA downstream of the cleavage site, consisting of any variation of 5’-NGG. Together with the core sgRNA, there are additional structures and RNA features like loops and hairpins needed for active and stable complex formation with Cas9 as detailed in Fig. 2 [30]. This site-specific DNA endonuclease system was first discovered in bacteria as a form of an 'adaptive immune response' to combat infections [31, 32]. Since then, investigators have exploited the core components of CRISPR-Cas9 to create site-specific gene edits in animal and human cell systems for a wide variety of applications (reviewed in [33]).

**CRISPR-Cas9 can be used for gene disruption and to regulate gene expression**

The conventional Cas9 protein consists of six domains, REC I, REC II, Bridge Helix, PAM-Interacting, HNH and RuvC [34, 35]. Rec I is the largest domain and mediates guide RNA binding. The role of the REC II domain has not yet been well-characterized. The arginine-rich Bridge Helix is critical for inducing cleavage activity upon DNA binding [35]. Initiation of binding to target DNA is mediated by the PAM-Interacting domain that confers PAM specificity [9, 34–36]. The Cas9 nuclease component contains the HNH and RuvC nuclease domains that cleave both the target and non-target strands of DNA, generating a double-stranded break (DSB) (Fig. 2a). Introduction of a DSB will induce either non-homologous end joining (NHEJ) or homology-directed repair (HDR) to correct the break (Fig. 3a). NHEJ occurs during all cell cycle phases and is considered error-prone since it can introduce random base pair insertions and deletions (indels), resulting in a pool of edited cells that can be clonally selected for gene knockout. Alternatively, co-delivery of a transgene template, where the template is flanked by homology arms upstream and downstream of the cut site, enhances high-fidelity homologous recombination repair leading to an insertion of the desired transgene into the target locus, which is restricted to G2/S phases of the cell cycle. The transgene insertion can consist of anything from an expression marker (e.g., fluorescent molecule), a selectable reporter, an element that will up- or down-regulate target gene expression, or an entirely new gene cassette [37].

**Different Cas9 delivery methods and enzyme variants can limit off-target editing**

DSB induction permits gene disruption and/or transgene insertion into target loci. However, there are risks associated with such breakage when it occurs at off-target sites, potentially introducing unintended genome alterations. Thus, precise control of when and where DSBs occur is beneficial for reducing the frequencies of unintended indels and translocations [38].
and preventing selection of p53 inactivated cells \[39, 40\]. It has been demonstrated that direct delivery of a pre-formed Cas9/gRNA ribonucleoprotein (RNP) complex into cells allows for Cas9 to be active immediately. The RNP is also quickly degraded once internalized, and therefore decreasing the amount of time Cas9 is present for potential off-target cleavage, but enough time to still maintain an optimal threshold of on-target editing efficiency \[41–43\].

Several Cas9 enzyme variants have also been developed to overcome the disadvantages of DNA DSB cleavage. For example, Nickase Cas9 (nCas9) variants contain mutations in either the RuvC or HNH domain which render Cas9 capable of cleaving only the targeted or non-targeted DNA strand, respectively \[44\] (Fig. 2b). The use of two pairs of nCas9/gRNA complexes flanking a targeted site allows for greater control of where a DSB can occur, as both complexes need to be at the same cut site for inducing the DSB, allowing for reduced off-target DSB generation \[45\]. Mutations in both catalytic domains create a catalytically dead Cas9 (dCas9) variant (Fig. 2c). dCas9 can easily be tethered to other functional enzymes to elicit a variety of site-specific modifications, independently of Cas9 catalytic activity \[46\].

**Base editors can be used to introduce single base pair transitions**

In the process of base editing (Fig. 3b), introduction of DNA point mutations can create or repair single nucleotide variants, modify donor and acceptor splicing sites, alter codon composition to change an amino acid code or introduce a premature STOP codon \[47–49\]. Accordingly, base editors can introduce four transition mutations that substitute a pyrimidine for another pyrimidine or purine for another purine (CT, TC, GA, AG) \[48\]. The enzymes used to catalyze these reactions are cytidine and adenosine deaminases. Cytidine deaminase induces the deamination of cytosine bases to uracil. During DNA replication, DNA polymerase ‘reads’ uracil as thymine, as these bases have the same base-pairing properties, resulting in a functional cystine-to-thymine correction in the nascent DNA strand. Adenosine deaminase acts in a similar manor, catalyzing the deamination of adenosine to inosine (I), which is ‘read’ by DNA polymerase as a guanine \[50\]. Base editing acts within a small window of specificity when directed to a precise site via a guide RNA (i.e., 13–18 base pairs upstream of the PAM site) \[48\]. To avoid off-target cuts \[51–55\] while achieving maximal editing efficiency, several Cas9 and deaminase variants have been developed that exhibit different PAM specificities \[56–58\] or editing windows \[59–61\].
Initial base editors relied on dCas9, but more recent investigations demonstrated that nCas9 is preferred for higher editing efficiency, as it can nick the non-edited strand to encourage the C-U or AI modified strand to be used as the template during DNA repair, resulting in a fully preserved edit [50]. Cytidine deaminase base editors are commonly used to generate premature STOP codons during transcription [48]. Finally, adenosine deaminase base editors can be used to alter splice donor/acceptor sites.

**Prime editors can be applied to introduce transversions and deletions or insertions**

A major limitation of base editing is that it cannot be applied to introduce transversion mutations (i.e., pyrimidine to purine and vice versa) as well as small deletions or insertions. To address this constraint, an alternative technology known as ‘prime editing’ was developed to facilitate all possible base-to-base conversions and targeted insertions or deletions without inducing DSBs [62]. In this strategy, nCas9 is tethered to an engineered reverse transcriptase (RT) enzyme and a prime editing guide RNA (pegRNA) forms a complex that can be used to introduce larger sequence additions into a DNA region without creating DSBs. Enzymatically dead Cas9 (dCas9) can be tethered to transcriptional activators (e.g., VP64) to potentiate transcription at a specific promoter region targeted by the gRNA, while transcriptional repressors (e.g., KRAB) can attenuate transcriptional activity. dCas9 can be tethered to epigenetic modifying enzymes to catalyze demethylation (e.g., TETs) or active methylation (DNMTs) for temporal regulation of epigenetic motifs and transcriptional activity at gRNA-specified loci promoters. Created with BioRender.com
editing strategy). After nicking the unedited strand, the cellular DNA repair machinery corrects this lesion using the initial pegRNA-edited strand as a template, which leads to the full establishment of the desired gene edit at the target locus (Fig. 3b). Prime editors are capable of not only inducing base pair resolution substitutions, but also insertions of up to 44 base pairs and deletions as high as 80 base pairs [63]. Thus, like base editors, prime editors can be used to modify post-mitotic cells and demonstrate a reduced risk for genotoxicity that often accompanies the generation of multiple DSBs. Current strategies modulating the enzyme activity [64, 65] or the pegRNA structure have been undertaken to further improve the efficiency of prime editing [54, 66].

*Catalytically dead Cas9 fused to transcriptional modulators can be used to regulate locus-specific gene expression*  

dCas9 can be used to promote or attenuate transcriptional activity based on recruitment of transcriptional activators or repressors to specific sites in the processes of CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi), respectively [67–70] (Fig. 3c). CRISPRi incorporates a tethered transcriptional repressor such as a Krüppel associated box (KRAB) domain to induce repression of transcription at the specified transcriptional start site [46, 71]. Alternatively, CRISPRa involves tethering of transcriptional activators such as VP64 to promote endogenous gene expression [46, 72]. In addition, tethering demethylating ten-eleven translocation (TET) methylcytosine dioxygenases or DNA methyltransferases (DNMTs) can permit locus and region-specific epigenetic modifications [73, 74] (Fig. 3c). This strategy has previously been used to target hypermethylated promoter regions of tumor-suppressor genes [75].

**Prospects for improving CAR T-cell Therapy with CRISPR-Cas9 gene editing**  

CRISPR-Cas9-mediated gene editing can be exploited to ameliorate CAR T-cell dysfunction  

Numerous factors often collectively prevent durable remissions following CAR T-cell therapy, including autologous CAR T-cell manufacturing issues, limited CAR T-cell expansion and/or persistence as well as various T-cell-intrinsic and -extrinsic resistance mechanisms (Fig. 4a). Recent studies indicate that chronic exposure to high levels of antigen leads to a state of T-cell exhaustion. Tumors, by providing a persistent source of antigen, can drive the establishment of T-cell exhaustion signatures at the time of apheresis, done to harvest T-cells for cell manufacturing, as a major predictor of clinical outcome [20].

Several approaches have been taken to improve the survival and function of CAR T-cells, including optimization of costimulatory endodomains [77], prevention of tonic signaling [78], inhibition of NRP4A transcription factors [79], TOX/TOX2 blockade [80] and overexpression of the canonical AP-1 factor, c-Jun [81]. Recently, global analysis of histone modifications in T-cells has elucidated marked differences in the chromatin structure of distinct subsets of exhausted T-cells and their transcriptional regulators (reviewed in [82]). Weber and colleagues [83] recently demonstrated that transient cessation of antigen receptor signaling through forced downregulation of the CAR protein or inhibition of proximal CAR signaling kinases restores functionality in exhausted T-cells through global and site-specific chromatin remodeling. Because intermittent CAR T-cell ‘rest’ mitigates exhaustion and enhances antitumor potency in association with epigenetic reprogramming, engineering loss-of-function or modulation of genetic and epigenetic targets that potentiate T-cell exhaustion using CRISPR-Cas9 technology has the potential to prevent and perhaps even reverse CAR T-cell dysfunction. Targeting inhibitory receptors, transcription factors and/or other mediators of CAR T-cell dysfunction through gene editing may induce reinvigoration of infused cell products. Removing negative regulators of CAR T-cell persistence and effector function (e.g., PD-1, CTLA-4 and LAG-3) using CRISPR-Cas9 may indeed represent a first obvious tractable point of intervention [84–87]. In addition to inhibitory receptors, disruption of Fas receptor/Fas ligand interactions have been shown to reduce activation-induced cell death and potentiate increased in vivo CAR T-cell antitumor function [88]. Finally, CRISPR/Cas9-mediated targeting of diacylglycerol kinase (DGK) metabolism in CAR T-cells renders them resistant to immunosuppressive mediators in the TME, such as TGFβ [89].

CRISPR/Cas9-mediated cytokine modulation potentiates CAR T-cell function and reduces toxicity  

Genetic strategies to modulate cytokine signaling during CAR T-cell activation and expansion have the potential to bolster antitumor activity, enhance T-cell persistence and/or reduced toxicity. CRISPR-Cas9 systems that incorporate transgene knock-in approaches have been exploited for this purpose. More specifically, CRISPR/Cas9-based gene editing combined with viral or
non-viral DNA delivery permits simultaneous bi-allelic or sequential gene targeting to engineer T-cells with expression cassettes in a site-specific manner [90, 91] (Fig. 4b). Using this technology, cytokine-encoding DNA cassettes can be knocked into targeted genomic loci placing these genes under the control of specific promoters for temporal control of expression. For example, IL-15 has been knocked into the IL-13 gene locus, thus placing IL-15 expression under control of the endogenous IL-13 promoter, which is highly active upon T-cell activation. This creates an inducible T-cell specific IL-15 activation switch [92]. Additionally, removal of genes encoding cytokines that drive neurotoxicity and cytokine release syndrome (CRS) such as GM-CSF [93] and IL-6 [94] with CRISPR-Cas9 editing has the potential to produce an optimally potent and durably persistent cell product, while reducing adverse events associated with aberrant cytokine production. Accordingly, GM-CSF knockout CAR T-cells maintain normal functions and increased antitumor activity in vivo, and potentiate improved overall survival, compared to conventional CD19 CAR T-cells [93]. Genetic knockdown or ablation of the IL-6 gene also has the potential to ameliorate CRS-like toxicity in leukemia-bearing mice [95] (Fig. 4c).

**CRISPR-Cas9 technology can be applied to knocking-in CAR cassettes**

Many current CAR T-cell manufacturing protocols involve ex vivo autologous T-cell expansions followed by transduction with a viral vector containing the chimeric receptor sequence [96]. While lentiviral transduction and integration is stable and considered generally safe for clinical trials and FDA-approved treatments [97], there are possible risks for malignant transformation of engineered CAR T-cells via insertional mutagenesis of tumor suppressor genes or oncogenes [98]. Additionally, since...
lentiviruses integrate semi-randomly in the genome, the CAR transgene can insert in sites with high or low relative transcriptional activity, leading to variable cell-surface CAR expression, generating a sub-optimal therapeutic product [99]. Placing the CAR transgene under control of a strong exogenous promoter may also lead to high constitutive receptor expression. Elevated surface expression and interaction with other CAR receptors can generate ligand-independent tonic signaling in the absence of exogenous signal. This can induce both systemic production of cytokines as well as a cell profile that drives rapid transition to poor effector function and T-cell exhaustion [100, 101]. To address these caveats associated with lentiviral transduction, CRISPR-Cas9 can be used to deliver a CAR-encoding DNA cassette to a specific genomic location, allowing for targeted knock-in of the CAR into desired sites. For example, an anti-CD19 CAR can be directed to the T-cell receptor α constant (TRAC) locus, resulting in uniform CAR expression, reduced tonic signaling, decreased exhaustion and increased antitumor efficacy [90] (Fig. 4b) Targeting TRAC also gives the added benefit of producing a potential universal product.

Application of CRISPR-Cas9 in Universal CAR T-cell product generation

Clinical development of novel CAR T-cell therapies is often hampered by the low yield and poor functionality of mature, autologous peripheral blood T-cells from many elderly and heavily-pretreated patients. A proposed solution is the procurement of healthy donor leukocytes to produce 'universal' T-cells with optimized in vivo persistence and antitumor potency. However, generating off-the-shelf CAR T-cell products is challenging because multiple genome edits within finite numbers of differentiated T-cells are needed to prevent alloreactivity and immunogenicity as well as potentiate robust tumor-specific activity. The problem has been further exacerbated by a gap in the development of renewable sources of precision-engineered T-cells, largely resulting from bottlenecks in manufacturing and facile multiplexed genetic ablation strategies.

CRISPR-Cas9 can be used to engineer off-the-shelf allogeneic CAR T-cells

The primary challenge to overcome in the setting of allogenic products is the induction of graft-versus-host disease (GVHD), where the endogenous donor T-cell receptor recognizes ‘non-self’ surface human leukocyte antigen (HLA) molecules in the patient, eliciting an immune reaction. Healthy donor allogeneic CAR T-cells can be derived from patients’ previous HLA-matched hematopoietic stem cell transplant (HSCT) donor or from gene-edited cells which have been modified to allow them to be given to non-HLA matched subjects. There is increasing enthusiasm for the use of so-called ‘third party’ CAR T-cells’ (i.e., non-autologous T-cells). An off-the-shelf product would allow one to start with T-cells from healthy donors to create large quantities of universal tumor-specific T-cells that could be used in any patient without the need for HLA matching. This strategy would reduce costs, speed drug administration, and make the T-cell products accessible to lymphopenic and critically ill cancer patients that often do not have sufficient numbers of healthy T-cells for treatment. As proof-of-concept for this approach, CAR T-cells derived from healthy unrelated donors have conferred anti-leukemic efficacy in children and adults with relapsed ALL [102]. Ideally, universal T-cell products should have 3 essential characteristics: 1) resistance to recognition/rejection by host natural killer (NK) cells and T-cells, 2) optimized for potency, persistence and safety, and 3) available as on-demand therapeutics. Without the ability to incorporate such features, large-scale and reproducible low-cost production of high quality, safely engineered CAR T-cells cannot be achieved and the promise of cell therapies will remain elusive to vast populations of cancer patients around the world.

The T-cell receptor α constant (TRAC) locus has been extensively studied as an ideal target for both gene knockout and CAR knock-in [90, 91]. Placing the CAR transgene under control of the endogenous TRAC promoter will drive CAR expression in a stable and robust manner parallel to physiological TCR expression. This will also simultaneously knock out the endogenous TCR, which will eliminate GVHD concerns and allow for an allogenic T-cell product to be generated. Combining the CAR T-cell manufacturing process with simultaneous TCR knockout allows for a streamlined approach to universal CAR T-cell generation (Fig. 4b, c).

Application of multiplex editing and CRISPR-Cas9 variants can optimize universal CAR T-cell therapy

Successful multiplex CRISPR-Cas9 editing of CAR T-cells has been done with targeting inhibitory genes (e.g., PDCD1, PD-1) and those encoding death receptors such as CD95/Fas to prevent TME-mediated inhibition or apoptosis [88]. TRAC, PDCD1 and B2M triple knockout CAR T-cells have demonstrated robust anti-tumor function in in vitro and in vivo models incorporating CD19 and prostate stem cell antigen (PSCA)-directed CARs [86, 87]. In terms of the safety and clinical feasibility of such an approach, we conducted the first-in-human trial of multiplex CRISPR-Cas9 edited (i.e., TRAC, TRBC and PDCD1 knockout) T-cells with a transgenic TCR specific for tumor-associated antigen NY-ESO-1 in patients with myeloma and sarcoma [3]. Transfer
of gene-edited TCR-engineered T-cells into patients resulted in durable engraftment with edits at all three genomic loci [3]. Although not involving multiplex gene editing, generation of PD-1 deficient T-cells via CRISPR-Cas9 editing of PDCD1 was also demonstrated to be feasible in the setting of clinical product scalability, and this product proved to be safe in a phase I trial for advanced non-small-cell lung cancer patients [4]. The results of the above investigations clearly demonstrate the feasibility and short-term safety of treating patients with CRISPR-edited human T-cells. Favorable outcomes from additional studies conducted with larger numbers of patients should hopefully justify more advanced Phase II and Phase III trials in the future (Fig. 4c).

The aforementioned Cas9 variants have shown promise in the pre-clinical setting. For example, primary human T-cells have been modified using base editors for disruption of TRAC, B2M and CIITA to reduce expression of the endogenous TCR, together with MHC class I and II machinery as well as PDCD1 to prevent additional inhibition of CAR T-cell effector function [103, 104]. Base editors have also shown promising therapeutic potential for enhancing CAR T-cells for treatment of T-cell acute lymphoblastoid leukemia (T-ALL). The CAR antigens for T-ALL are typical pan T-cell markers such as CD7 and CD3, and anti-CD7 CAR T-cells for T-ALL have already been proven safe and efficacious in Phase I clinical trials [105]. Introduction of premature STOP codons into the CD7 and CD3 loci of anti-CD7 and anti-CD3 CAR T-cells prevents the induction of CAR-mediated fratricide during the manufacturing and infusion process [106]. dCas9 tethered to transcriptional repressor KRAB targeting the PDCD1 gene is effective in generating anti-HER2 CAR T-cells with low PD-1 expression to confer checkpoint inhibition resistance [107]. Prime editors, while still in their infancy, can efficiently edit the genomes of human cell lines and human primary T-cells [108]. The search-and-replace nature of prime editing also provides a potentially more adaptable method to simultaneously introducing additional complex gene edits into T-cells (e.g., certain gain of function mutations) that can enhance CAR T-cell therapy, but are challenging to achieve with endonuclease-based gene or base editing approaches (Fig. 4c).

The challenges of producing a universal CAR T-cell product from finite numbers of mature, fully differentiated healthy donor T-cells are compounded by the anticipated engineering demands, particularly for solid tumors in which multiple CRISPR-Cas9-based gene edits are needed to be combined with CAR-based recognition to achieve safety and efficacy. For example, in the setting of allogeneic T-cell therapies involving checkpoint blockade, expression of a transgene encoding a synthetic antigen receptor is required, in addition to knockout of several inhibitory molecules (e.g., PD-1, CTLA-4, TIM-3, LAG-3) as well as T-cell receptor (TCR) alpha and beta constant regions (TRAC and TRBC). As these therapies require several genetic edits within mature T-cells, inefficiencies and combinatorial stochasticity in production result in a final product that typically contains many different populations of cells with variable editing combination efficiencies that need to be evaluated and optimized to increase efficacy [103].

To specifically address cell source material to generate allogeneic products, CAR T-cell therapeutics can be derived from inducible pluripotent stem cells (iPSCs) amenable to genetic modification and differentiation into mature tumor-targeted T-cells. iPSCs are obtained from adult somatic cells by inducing expression of a combination of transcription factors (c-MYC, OCT3/4, SOX2 and KLF4) that transform cells into a pluripotent state [109, 110] (Fig. 4c). Pluripotent stem cells can give rise to the three embryonic germ layers, rendering them capable of differentiating into any specified cell type, with lymphoid lineages stemming from mesoderm progenitors [111, 112]. Because iPSCs are stem-like cells, they can be cultured unlimitedly and indefinitely in vitro under proper conditions which allow for a continuous production of T-cells [111]. Proof-of-concept studies have demonstrated successful generation of CAR T-cells from T lymphocyte-derived iPSCs [113]. However, the use of ‘feeder-free’ culture systems will likely be necessary for clinical-grade scalability and production [114]. Ideal conditions to achieve differentiation of mature T-lymphocytes involve incorporation of thymic niche promoting Notch/TCR signaling, as well as soluble factors such as IL-7, FMS-like tyrosine kinase 3 ligand (FLT3), stem cell factor (SCF), and the chemokines CXCL12 and CCL25 [111, 114].

Because downstream differentiated T-cells are derived from the same iPSC clone, CRISPR-Cas9 editing of iPSCs permits stable and consistent knockdown of factors such as the endogenous TCR and major histocompatibility complex (MHC) genes as well as genes encoding inhibitory molecules such as PD-1 to create unique pools of allogeneic T-cell products with superior antitumor functionality, as has been previously seen in edited primary T-cells directed against glioblastoma and acute lymphoblastic leukemia in vivo models [90, 115]. Ideally, this will lead to a bank of selected iPSC lines with a consistent and optimally potent downstream differentiated final product for off-the-shelf therapies (Fig. 4c). The combination of precision iPSC programming using CRISPR-Cas9 and CAR technology sets the stage for the emergence of a new class of renewable and highly controllable off-the-shelf T-cell therapeutics.
Conclusions

The clinical efficacy of CAR T-cell technology has been proven in the setting of human cancer. However, there are major limitations to accessing this technology. Currently, it is a bespoke product made for individual patients, and therefore, the time to manufacture can prevent access as can the cost. Further, the T-cells used as starting material from patients are likely to have developed cancer associated T-cell dysfunction, which may not be reversible. Advances in CRISPR-Cas9-based genome editing will help address the several current unmet needs in CAR T-cell therapy. Such advances may involve DSB-free genome editing methods like base and prime editing to allow precise and controllable genetic modification in a robust manner. In addition, CRISPR-Cas9-induced multiplex knockout of inhibitory molecules potentiates enhanced CAR T-cell expansion and persistence that may allow for circumvention of T-cell-intrinsic as well as -extrinsic resistance mechanisms operative in both hematopoietic and non-hematopoietic malignancies. Targeted knock-in approaches also have the potential to fine-tune transgene insertion during CAR T-cell engineering to generate effective and potent cell products with temporally regulated effector functions. Finally, procurement of normal donor leukocytes or iPSCs to produce a ‘universal’ CAR T-cell product that can be CRISPR-Cas9 engineered to overcome certain histocompatibility barriers and with enhanced persistence/antitumor function will significantly improve the manufacturing of cellular immunotherapies and therapeutic durability. Development of next-generation therapies with CAR T-cells, involving innovative genetic editing with CRISPR-Cas9 technology, will ultimately improve affordability and reduce off-target toxicities while enhancing antitumor effectiveness.

Abbreviations

ALL: Acute lymphoblastic leukemia; BCMA: B-cell maturation antigen; CAR : Chimeric antigen receptor; CLL: Chronic lymphocytic leukemia; Cas9: CRISPR-associated protein 9; CRISPR: Clustered regularly interspaced short palindromic repeats; CRISPRa: CRISPR activation; CRISPRi: CRISPR interference; CRISPR-associated protein 9; CRISPR: Clustered regularly interspaced short palindromic repeats; DSB: Double-stranded break; FDA: United States Food and Drug Administration; HDR: Homology-directed repair; HLA: Human leukocyte antigen; HDSC: Hematopoietic stem cell transplant; Indels: Insertions and deletions; iPSCs: Induced pluripotent stem cells; KRAB: Krüppel associated box; MHC: Major histocompatibility complex; nCas9: Nickase Cas9; NK cell: Natural killer cell; NHEJ: Non-homologous end joining; PAM: Protospacer adjacent motif; pegRNA: Prime editing guide RNA; RT: Reverse transcriptase; sgRNA: Single-guide RNA; TCR: T-cell receptor; TET: Ten-eleven translocation; TME: Tumor microenvironment; TRAC: T-cell receptor α-chain constant; TRBC: T-cell receptor β-chain constant.

Acknowledgements

Not applicable.

Authors’ contributions

AD, FH and JAF wrote the manuscript; AD created the figures; FH and JAF edited the manuscript multiple times to significantly enhance the quality; the authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors consent to publication.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, South Pavilion Expansion (SPE), Room 9-104, 3400 Civic Center Blvd, Bldg. 421, Philadelphia, PA 19104-5156, USA. 2Department of Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4Department of Translational Medical Oncology, National Center for Tumor Diseases, Dresden and German Cancer Research Center, Heidelberg, Germany. 5Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 6Department of Medicine, University of Pennsylvania, South Pavilion Expansion (SPE), Room 9-104, 3400 Civic Center Blvd, Bldg. 421, Philadelphia, PA 19104-5156, USA. 7Department of Pediatrics, University of Pennsylvania, South Pavilion Expansion (SPE), Room 9-104, 3400 Civic Center Blvd, Bldg. 421, Philadelphia, PA 19104-5156, USA. 8Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 9Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Received: 11 January 2022 Accepted: 4 March 2022

Published online: 18 March 2022

References

1. Gillmore JD, Maitland ML, Lebwohl D. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. Reply N Engl J Med. 2021;385:1722–3.
2. Frangoul H, Ho TW, Corbacioglu S. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. Reply. N Engl J Med. 2021;384:e91.
3. Stadtmueller EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:eaba3766.
4. Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, Huang M, Yi X, Liang M, Wang Y, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020;26:732–40.
5. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewksia M, et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci Transl Med. 2013;5:177ra138.
6. Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378:449–59.
7. Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. 2020;22:57–69.
8. June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med. 2018;379:64–73.
9. Sternberg SH, Redding S, Jinck M, Greene EC, Doudna JA. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature. 2014;507:62–7.
10. Roex G, Feys T, Beguin Y, Kerre T, Poire X, Levalle P, Vandenberghe P, Bron D, Anguille S. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Disease and beta-Thalassemia. Reply. N Engl J Med. 2021;384:e91.
Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceuticals. 2020;12:194.

11. Zheng PP, Kros JM, Li J. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Discov Today. 2018;23:1175–82.

12. Van Zelm MC, Reisli I, Van Der Burg M, Castaño D, Van Noesel CJM, Van Tol MJ, Woelber C, Grimbacher B, Patroni P, Van Dongen JIM, Franco JL. An Antibody-Deficiency Syndrome Due to Mutations in the CD19 Gene. N Engl J Med. 2006;354:1901–12.

13. Nishihausa H, Hanaoka F, Hata H, Kasahara T, Iida T, Suda T. A bcl-2 transgenic mouse model for chronic lymphocytic leukemia. Nature. 1989;337:86–8.

14. Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy. Nature. 2021;20:332.

15. Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumers D, Schroyens W, Chuy S, Bernetman ZN, Lion E, Luo F, Angueliu S. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020;13:164.

16. Adams A, Mahler J. An overview of CAR-T cell clinical trial activity to 2021. Immunother Adv. 2021;1:10004.

17. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Personj S, Schimerber B, Taipale J. CAR T-cell therapy. N Engl J Med. 2015;373:517–28.

18. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory receptor-based fusion proteins for cancer immunotherapy. Mol Ther. 2015;23:1175–82.

19. Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M. CRISPR/Cas9 gene targeting for the treatment of hematological diseases. Curr Issues Mol Biol. 2018;26:15–32.

20. Chong EA, Ruella M, Schuster SJ. Lymphoma Program Investigators at the University of P: Five-Year Outcomes for Refractory B-Cell Lymphomas in 2014;546:161–74.

21. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory receptor-based fusion proteins for cancer immunotherapy. Mol Ther. 2015;23:1175–82.

22. Casovsky D, Xu L, Li Y. T-cell senescence and CAR-T cell exhaustion in hematological malignancies. J Hematol Oncol. 2018;11:91.

23. Kim S, Kim D, Cho SW, Kim J, Kim J-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014;24:1012–9.

24. Trevino AE, Zhang F. Genome Editing Using Cas9 Nickases. Elsevier. 2014;3:e04766.

25. Kim S, Kim D, Cho SW, Kim J, Kim J-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014;24:1012–9.

26. Kuscu C, Parlak M, Tufan T, Yang J, Szlachta K, Wei X, Mammadov R, Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of A*T to G*C in genomic DNA by Cas9-D10A mutants. Nat Methods. 2017;14:380–9.

27. Brocken JW, Tark-Dame M, Dame R, McPhee P, Kocak M, Kocak M, Tark-Dame M, Dame R, McPhee P, Kocak M, Kocak M. CRISPR-Cas9 for Enhanced Genome Editing Specificity. Cell. 2013;154:1380–9.

28. Komor AC, Kim YB, Parker MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2014;533:420–5.

29. Ishida K, Ararone T, Yachie N, Banno S, Sakimoto T, Mabata M, Mochizuki M, Miyabe A, Araki M, Han K, et al. Targeted nucleotide editing of A:T to G:C in genomic DNA by CRISPR. Nature. 2016;531:506–30.

30. Kazazian HU, Shendure J. CRISPR-Cas9 for genome editing in human pluripotent stem cells. Nat Biotechnol. 2015;33:73–80.

31. Zhou C, Sun Y, Yan R, Liu Y, Zuo E, Gu C, Han L, Wei Y, Hu X, Zeng R, et al. OFF-target RNA mutations induced by RNA base editing and its elimination by megatransgenesis. Nature. 2019;571:275–8.
54. Lin Q, Jin S, Zong Y, Yu H, Zhu Z, Liu G, Kou L, Wang Y, Qiu JL, Li J, Gao C. High-efficiency prime editing with optimized, paired pegRNAs in plants. Nat Biotechnol. 2021;39:923–7.
55. Richter MF, Zhao KT, Eton E, Lapinaite A, Newby GA, Thuronyi BW, Wilson C, Koblan LW, Zeng J, Bauer DE, et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature. 2015;523:481–5.
56. Hu JH, Miller JD, Geurts MH, Tang W, Chen L, Sun N, Zeina CM, Gao X, Rees HA, Lin Z, Liu DR. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. 2018;556:57–63.
57. Miller SM, Wang T, Randolph PB, Arbab M, Shen MW, Huang TP, Matuszek Z, Newby GA, Rees HA, Liu DR. Continuous evolution of ScSpCas9 variants compatible with non-G PAMs. Nat Biotechnol. 2020;38:471–81.
58. Zafrir MP, Scharoff EM, Katti A, Foronda M, Breinig M, Schweitzer AY, Simon A, Han T, Goswami S, Montgomery E, et al. Optimized base editors enable efficient editing in cells, organoids and mice. Nat Biotechnol. 2018;36:888–93.
59. Huang TP, Newby GA, Liu DR. Precision genome editing using cytosine and adenosine base editors in mammalian cells. Nat Protoc. 2021;16:1089–128.
60. Gaudelli NM, Lam DK, Rees HA, Sola-Estives NM, Barrera LA, Born DA, Edwards A, Gehrke JM, Lee SJ, Liquori AJ, et al. Directed evolution of adenosine base editors with increased activity and therapeutic application. Nat Biotechnol. 2020;38:892–900.
61. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A, Liu DR. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149–57.
62. Newby GA, Liu DR. In vivo somatic cell base editing and prime editing. Mol Ther. 2021;29:3107–24.
63. Park S-J, Jeong TY, Shin SK, Yoon D, Kim SP, Cunanan KM, Odak A, Gonen M, Sadelain M. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2019;569:647–61.
64. Gilbert LA, Holtbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead-EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell. 2013;154:442–51.
65. Gilbert LA, Holtbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead-EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell. 2014;159:647–61.
66. Lei M, Luke J, Jonathan A, Wendell. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. Cell. 2013;152:1173–83.
67. Nunez JK, Chen J, Pommier GC, Cogan JZ, Replogle JM, Adriaens C, Ramadoss GN, Shi Q, Hung KL, Samelson AJ, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell. 2021;184:2503–19 (e2517).
68. Gilbert L, Holtbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead-EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell. 2014;159:647–61.
69. Maeder ML, Linder S, Casimo VM, Fu Y, Ho QH, Joung JK. CRISPR RNA—guided activation of endogenous human genes. Nat Methods. 2010;7:987–90.
70. Kang JG, Park JS, Ko I-H, Kim Y-S. Regulation of gene expression by altered promoter methylation using a CRISPR/Cas9-mediated epigenetic editing system. Scientific Reports. 2019;9:11960.
71. Lu A, Wang J, Sun W, Huang W, Cai Z, Zhao G, Wang J. Reprogrammable CRISPR/Cas9-based recruitment of DNM1T1 for site-specific DNA demethylation and gene regulation. Cell Discovery. 2019;5(2).
72. Choudhury SR, Cui Y, Lubeka B, Stefanska B, Irudayaraj J. CRISPR-Cas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. Oncoarget. 2016;7:46545–56.
73. Jiang W, He Y, He W, Wu G, Zhou X, Sheng Q, Zhong W, Lu Y, Ding Y, Lu Q, et al. Exhaled CDB+ T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. Frontiers in Immunology. 2021;11:622509.
74. Navekar JS, O’Connor RS, Fraietta JA, Guo L, McGavigan SE, Posey AD, Patel PR, Guedan S, Scholler J, Keith B, et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 2016;44:380–90.
75. Long AH, Haso WM, Shern JF, Wahnainen KM, Murgai M, Ingranno M, Smith JP, Walker AJ, Kohler ME, Venikateshwarara V, et al. 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581–90.
76. Chen J, López-Moyado IF, Seo H, Liu CW, Hemplenburger L, Sekiya T, Yoshimura A, Scott-Browne JP, Rao A. NHR4 transcription factor limits CART cell function in solid tumours. Nature. 2019;567:530–4.
77. Liang C, Huang S, Zhao Y, Chen S, Li Y. TOX as a potential target for immunotherapy in lymphocytic malignancies. Biomarker Research. 2021;9:20.
78. Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, Anbunanathan H, Lattin J, Jones R, Tieu V, et al. Jun overexpression in ex vivo CART cells induces exhaustion resistance. Nature. 2019;576:293–300.
79. Wu J, Shi H. Unlocking the epigenetic code of T cell exhaustion. Translational Cancer Research. 2017;6:5384–7.
80. Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunanthan H, Lattin J, Good Z, Belk JA, Daniel B, Klysz D, et al. Transient rest restores functionality in ex vivo CART cells through epigenetic remodelling. Science (New York, NY). 2021;372:eaab1786.
81. Zhang Y, Zhang X, Cheng C, Mu W, Liu X, Li N, Wei X, Liu X, Xia C, Wang H. CRISPR-Cas9 mediated LAG-3 disruption in CART cells. Front Med. 2017;11:554–62.
82. Zhang W, Shi L, Zhao Z, Du P, Ye X, Li D, Cai Z, Han J, Cai J. Disruption of CTLA-4 expression on peripheral blood CD8+ T cells enhances anti-tumor efficacy in bladder cancer. Cancer Chemother Pharmacol. 2019;83:911–20.
83. Liu X, Zhang Y, Cheng C, Cheng AW, Zhang X, Li N, Xia C, Wei X, Liu X, Wang H. CRISPR-Cas9-mediated multiplex gene editing in CART cells. Cell Res. 2017;27:154–7.
84. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex Genome Editing to Generate Universal CART Cells Resistant to PD1 Inhibition. Clin Cancer Res. 2017;23:2255–66.
85. Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y. A versatile system for rapid multiplex genome-edited CART cell generation. Oncoarget. 2017;8:17002–11.
86. Jung IY, Kim YY, Yu HS, Lee M, Kim S, Lee J. CRISPR/Cas9-Mediated Knockout of DKG Improves Antitumor Activities of Human T Cells. Cancer. 2018;74:4962–703.
87. Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Hansen MJ, Jin F, Ayasoufi K, Heafey K, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543:113–7.
88. MacLeod DT, Antony J, Martin AJ, Moser RJ, Heake E, Wetzel KJ, Brown AE, Triggiano MA, Hux JA, Pham CD, et al. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CART T Cells. Mol Ther. 2017;25:1547–54.
89. Ode Z, Condori J, Peterson N, Zhou S, Krenicute G. CRISPR-Cas9-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy. Cancers (Basel). 2020;12:1704.
90. Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Heafey K, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133:679–707.
91. Robonant CL, Jackson HJ, Brentjens RJ, Curran KJ, Toxicity and management in CAR-T cell therapy. Mol Ther Oncolytics. 2016;3:16011.
92. Kang L, Tang X, Zhang J, Li M, Xu N, Q, Wang T, J, Sun J, et al. Interleukin-6 knockdown of chimeric antigen receptor-modified T cells
significantly reduces IL-6 release from monocytes. Exp Hematol Oncol. 2020;9:11.

96. Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomarker Research. 2017;5(22).

97. McGarrity GJ, Hoyah G, Winemiller A, Andre K, Stein D, Bluck G, Greenberg RN, Kinder C, Zolopa A, Binder-Scholl G, et al. Patient monitoring and follow-up in lentiviral clinical trials. J Gene Med. 2013;15:78–82.

98. Schlimmgen R, Howard J, Wooley D, Thompson M, Baden LR, Yang QG, Christani DC, Mostoslavsky G, Diamond DV, Duane EG, et al. Risks Associated With Lentiviral Vector Exposures and Prevention Strategies. J Occup Environ Med. 2016;58:1159–66.

99. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther. 2005;16:1241–6.

100. Frigault MJ, Lee J, Basel MC, Carpenito C, Motohashi S, Scholler J, Kavalekar OU, Guedan S, McGgettigan SE, Posey AD, et al. Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells. Cancer Immunol Res. 2015;3:356–67.

101. Ajina A, Maher J. Strategies to Address Chimeric Antigen Receptor Tonic Signaling. Mol Cancer Ther. 2018;17:1795–815.

102. Benjamin R, Graham C, Tallo D, Jozwik A, Mirci-Danicar OC, Lucchini M, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Ajina A, Maher J. Strategies to Address Chimeric Antigen Receptor Tonic Signaling. Mol Cancer Ther. 2018;17:1795–815.

103. Webber BR, Lonetree C-L, Kluesner MG, Johnson MJ, Pomeroy EJ, Diers AJ, Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini M, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Ajina A, Maher J. Strategies to Address Chimeric Antigen Receptor Tonic Signaling. Mol Cancer Ther. 2018;17:1795–815.

104. Gaudelli NM, Lam DK, Rees HA, Solà-Esteves NM, Barrera LA, Borr DA, Edwards A, Gehrke JM, Lee S-J, Liqouri AJ, et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat Biotechnol. 2020;38:892–900.

105. Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, et al. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. J Clin Oncol. 2021;39:3340–51.

106. Georgiadis C, Rasalyaah J, Gkazi SA, Preece R, Etuk A, Christi A, Qasim W. Base-edited CART T cells for combinational therapy against T cell malignancies. Leukemia. 2021;35(12):3466–81.

107. Yang Z, Li L, Turkoz A, Chen P, Harani-Steinfeld R, Bobbin M, Stefansson O, Choi H, Pietrobon V, Alphson B, et al. Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers. J Translat Med. 2021;19:459.

108. Pett K, Zhang W, Ma J, Schmidts A, Lee H, Horng JE, Kim DY, Kurt IC, Clement K, Hsu JY, et al. CRISPR prime editing with ribonucleo-protein complexes in zebrafish and primary human cells. Nature Biotechnology. 2021;40(2):189–93.

109. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.

110. Park IH, Zhao R, West JA, Yabuuchi A, Hsu J, Ince TA, Lerou PH, Lensch MW, Daley GQ. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451:141–6.

111. Nianias A, Themeli M. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges. Curr Hematol Malig Rep. 2019;14:261–8.

112. Flahou C, Morishima T, Takizawa H, Sugimoto N. Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity. Front Immunol. 2021;12:662360.

113. Themeli M, Kloss CC, Cirelli G, Fedorov VO, Perna F, Gonen M, Sadelain M. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31:928–33.

114. Iriuchi S, Yasui Y, Kawai Y, Arima S, Kunitomo M, Sato T, Ueda T, Minagawa A, Mishima Y, Yanagawa N, et al. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nat Commun. 2021;12:430.

115. Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, Larson RC, Scarfo I, Bailey SR, Gerhardt GA, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII+ CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019;7:304.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.